QT Interval
Conditions
Brief summary
The purpose of this study is to demonstrate that telotristat etiprate does not differ from placebo in the mean change from Baseline QT interval corrected for heart rate.
Interventions
1500 mg telotristat etiprate (six 250 mg tablets)
DRUGPlacebo
Matching placebo
DRUGMoxifloxacin
400 mg moxifloxacin (one 400 mg tablet)
Sponsors
Lexicon Pharmaceuticals
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy adult males or females ≥18 to ≤55 years of age (inclusive) at the time of Screening * Body mass index ≥18 to ≤32 kg/m2 at Screening * Vital signs (after at least 5 minutes resting in a supine position) at Screening which are within the following ranges: Systolic blood pressure 90 to 140 mm Hg, Diastolic blood pressure 50 to 90 mm Hg, heart rate 45 to 100 beats per minute (bpm) * Clinical laboratory evaluations (including clinical chemistry panel \[fasted at least 10 hours\], complete blood count, and urinalysis \[UA\]) within the reference range for the test laboratory, unless deemed not clinically significant by the Investigator * Able to tolerate prolonged periods of quiet, motionless, supervised rest * Willing to adhere to the prohibitions and restrictions specified in this protocol * Able to comprehend and willing to sign an Informed Consent Form
Exclusion criteria
* Presence of clinically significant physical, laboratory, or ECG findings at Screening that, in the opinion of the Investigator or Sponsor, may interfere with any aspect of study conduct or interpretation of results * \>30 premature ventricular beats per hour on the Holter ECG monitoring at Day -1 of Period 1 (monitored at the clinic via telemetry) * History of additional risk factors for torsade de pointes or the diagnosis or suggestion of a family history of short QT syndrome or long QT syndrome * History of renal disease or significantly abnormal kidney function tests * History of hepatic disease or significantly abnormal liver function tests * History of any clinically significant psychiatric, renal, hepatic, pancreatic, cardiovascular, neurological, or gastrointestinal abnormality * Concurrent conditions that could interfere with safety and tolerability measurements * Positive hepatitis panel (including hepatitis B surface antigen and hepatitis C virus antibody) or positive human immunodeficiency virus antibody screens * Use of tobacco, use of medications, or history of any disease or condition that might interfere with the conduct of the study in the opinion of the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean change from baseline QT interval corrected for heart rate | Days 1-3 |
Secondary
| Measure | Time frame |
|---|---|
| Number of adverse events | 52 days |
| Plasma concentration of telotristat etiprate | Day 1 |
Countries
United States
Outcome results
None listed